ライフサイエンスコーパス: intracoronary

1 tervention (n=80) were randomized to receive intracoronary (10 mL) sodium nitrite (1.8 mumol) or NaCl

2 Under control conditions (intracoronary 5% dextrose in water), atrial-pacing tachy

3 Patients randomized to intracoronary abciximab also had a significant reduction

4 improve outcomes after primary PCI are bolus intracoronary abciximab and manual aspiration thrombecto

5 The intracoronary abciximab bolus did not reduce the primary

6 Administration of an intracoronary abciximab bolus during primary percutaneou

7 Patients randomized to intracoronary abciximab compared with no abciximab had a

8 y reduced in diabetic patients randomized to intracoronary abciximab compared with those randomized t

9 open-label, 2 x 2 factorial design to bolus intracoronary abciximab delivered locally at the infarct

10 t 30 days was significantly reduced by bolus intracoronary abciximab delivered to the infarct lesion

11 icantly less congestive heart failure in the intracoronary abciximab group.

12 c patients with STEMI, the administration of intracoronary abciximab improved the effectiveness of pr

13 resent in 181 and 172 patients randomized to intracoronary abciximab vs no abciximab, respectively, a

14 e epicardial vasoconstriction in response to intracoronary acetylcholine (-19+/-2% versus -14+/-1% ch

15 -four patients of the latter (86%) underwent intracoronary acetylcholine (ACH) testing, which elicite

16 However, provocation tests using intracoronary acetylcholine administration are rarely pe

17 The intracoronary acetylcholine provocation test is a safe t

18 angiographic characteristics, and safety of intracoronary acetylcholine provocation testing in white

19 The intracoronary acetylcholine provocation testing was perf

20 ACS patients without culprit lesion, in whom intracoronary acetylcholine provocation was performed, h

21 mized (3:1 ratio) to receive 1 of 5 doses of intracoronary Ad5.hAC6 or placebo.

22 Thirty-nine patients received intracoronary adeno-associated virus type 1/sarcoplasmic

23 coronary flow reserve was examined by use of intracoronary adenosine and nitroglycerin.

24 d baseline coronary flow reserve (CFR) after intracoronary adenosine in 189 women referred to evaluat

25 endent) coronary flow reserve in response to intracoronary adenosine were evaluated.

26 y measurements were performed at rest, after intracoronary adenosine, and during increasing infusion

27 ty was not different between intravenous and intracoronary administration (1.47% versus 1.33%; P=0.5)

28 Intracoronary administration of Ad5.hAC6 (3.2 x 109 to 1

29 Preclinical studies with intracoronary administration of Ad5FGF-4 (alferminogene

30 The modest effects of clinical studies using intracoronary administration of autologous bone marrow-d

31 Intracoronary administration of autologous bone marrow-d

32 Intracoronary administration of autologous CDCs did not

33 hronic heart failure, shock wave-facilitated intracoronary administration of BMCs vs shock wave treat

34 Intracoronary administration of CDCs has been demonstrat

35 Intracoronary administration of CPCs in the setting of a

36 model of AMI relevant to the human disease, intracoronary administration of IGF-1/HGF is a practical

37 day outcome in 775 consecutive procedures of intracoronary administration of progenitor cells using t

38 p, n=9) were compared with animals receiving intracoronary AdvEGFP (2x10(12) vp, n=6).

39 d regional function before and 30 days after intracoronary AdvFGF-5 (2x10(12) vp, n=9) were compared

40 hodology, we compared the efficacy of global intracoronary allogeneic MSCs (icMSCs, approximately 35x

41 tematically compared FFR measurements during intracoronary and intravenous application of adenosine a

42 52) did not differ significantly between the intracoronary and the intravenous abciximab groups.

43 In an open-label blinded study, we compared intracoronary and transendocardial CD34(+) cell transpla

44 Intracoronary angiotensin-converting enzyme inhibitors h

45 c reperfusion was performed for 90 min using intracoronary AO.

46 Limited data validate the intracoronary application of adenosine against standard

47 Reported discomfort after intracoronary application was significantly lower compar

48 interval between arrival at the hospital and intracoronary balloon inflation (door-to-balloon time) d

49 ee cycles of 10/10 min r-I/R by percutaneous intracoronary balloon inflation/deflation in the mid lef

50 tions were by immunoblotting in systemic and intracoronary blood from independent cohorts of patients

51 ry cells in the infarct border zone, whereas intracoronary BM cell injection provided more homogeneou

52 of NT-proBNP serum levels at 4 months after intracoronary BMC administration in patients with ICM, s

53 ntial impairment of kidney function received intracoronary BMC administration.

54 cell retention and determine the response to intracoronary BMC application in patients with ICM.

55 istics than on whether the patient underwent intracoronary BMC transplantation.

56 ated with primary PCI, the administration of intracoronary BMCs at either 3 days or 7 days after the

57 ention, 120 patients were randomized to a 1) intracoronary BMMC injection; 2) mobilization with G-CSF

58 intravenous infusion versus 23 +/- 14 s for intracoronary bolus administration of adenosine (P < 0.0

59 Intracoronary bolus administration of eptifibatide durin

60 Intracoronary bolus administration of eptifibatide may r

61 Two FFR measurements were performed during intracoronary bolus injection (40 mug for the right and

62 Intracoronary bolus injection of adenosine (40 mug for t

63 aseline and maximal hyperemia, induced by an intracoronary bolus of adenosine (20-40 microg).

64 Intracoronary bolus of apelin-36 increased coronary bloo

65 ly assigned 40 patients to receive either an intracoronary bolus of enalaprilat (50 mug) or placebo b

66 Intracoronary cardiospheres are also remarkably effectiv

67 Importantly, intracoronary cardiospheres decreased left ventricular e

68 We investigated long-term effects of intracoronary CD34+ cell transplantation in dilated card

69 myocardium offers a valuable alternative to intracoronary cell injections, and the use of allogeneic

70 erform a meta-analysis of clinical trials on intracoronary cell therapy after acute myocardial infarc

71 We analyzed the safety and efficacy of intracoronary cell therapy after acute myocardial infarc

72 Intracoronary cell therapy continues to be evaluated in

73 Intracoronary cell therapy following percutaneous corona

74 Subjects that received intracoronary cell therapy had a significant improvement

75 zed trials targeted to address the impact of intracoronary cell therapy on overall and event-free lon

76 databases for controlled trials reporting on intracoronary cell therapy performed in patients with a

77 ls in patients with recent AMI revealed that intracoronary cell therapy provided no benefit, in terms

78 Intracoronary cell therapy was also associated with a no

79 hearts of three different mammalian species, intracoronary chloroquine perfusion reduced fibrillatory

80 ased only in diabetic patients randomized to intracoronary compared with intravenous abciximab (54.4;

81 nt study was undertaken to determine whether intracoronary CSCs are beneficial in a porcine model of

82 farction, the dose-response relationship for intracoronary CSCs is flat.

83 etrospective multicentric registry and Mainz Intracoronary Database.

84 diated gene therapy strategy that is able to intracoronary deliver the combination of IL-4 and IL-10

85 Initially, intracoronary delivery conditions were optimized in 20 s

86 Ex vivo intracoronary delivery of adenovirus-mediated gene trans

87 ate the safety, feasibility, and efficacy of intracoronary delivery of allogeneic human cardiac stem

88 sed the safety, feasibility, and efficacy of intracoronary delivery of allogeneic MPCs directly after

89 test, for the first time, the feasibility of intracoronary delivery of an innovative, injectable bioa

90 Clinical trial results suggest that intracoronary delivery of autologous bone marrow mononuc

91 Harvesting, processing, and intracoronary delivery of BMCs in this setting was feasi

92 Intracoronary delivery of BNP116.I-1c was safe and impro

93 Intracoronary delivery of c-kit-positive human cardiac s

94 luating the safety and efficacy of optimized intracoronary delivery of cardiospheres in a porcine mod

95 Intracoronary delivery of cardiospheres is safe.

96 Intracoronary delivery of CDCs in a preclinical model of

97 rgitation induction, pigs were randomized to intracoronary delivery of either BNP116.I-1c (n = 6) or

98 after myocardial infarction, pigs underwent intracoronary delivery of either recombinant adeno-assoc

99 At 2 months, pigs underwent intracoronary delivery of either recombinant adeno-assoc

100 Intracoronary delivery of endothelial progenitor cells (

101 This first-in-man pilot study shows that intracoronary deployment of an IK-5001 scaffold is feasi

102 Intracoronary deployment of BCM 2 to 5 days after succes

103 efined as the successful manipulation of the intracoronary devices using the robotic system only.

104 onary pulse wave analysis, we calculated the intracoronary diastolic suction wave (the principal acce

105 d troponin, microemboli can be visualized by intracoronary Doppler and the resulting microinfarcts by

106 three patients were studied; in 24 patients, intracoronary Doppler flow velocity measurements were pe

107 y disease, and may be accurately assessed by intracoronary Doppler flow velocity measurements.

108 primary percutaneous coronary intervention, intracoronary Doppler flow velocity was measured in the

109 s calculated from flow velocity, measured by intracoronary Doppler, and luminal diameter, measured by

110 ith quantitative coronary angiography and an intracoronary Doppler-tipped guidewire.

111 u) responses were assessed during continuous intracoronary drug infusion in sinus rhythm followed by

112 There was a decrease in intracoronary ECG ST-elevation during RCA occlusion from

113 erve during vessel patency, the quantitative intracoronary ECG ST-segment elevation, and angina pecto

114 end point was the quantitatively determined intracoronary ECG ST-segment elevation.

115 Intracoronary ECG ST-segment elevations were significant

116 the second and third inflations, both on the intracoronary electrocardiogram (ECG) (21.0 +/- 2.8 mm v

117 Intracoronary enalaprilat improves coronary microvascula

118 This study investigated the influence of intracoronary enalaprilat on coronary microvascular func

119 l, or other adverse findings attributable to intracoronary eptifibatide.

120 This emphasizes the requirement of intracoronary flow assessment in addition to coronary pr

121 including quantitative coronary angiography, intracoronary flow velocity probes, and pharmacologic st

122 overexpression in pig hearts was achieved by intracoronary gene delivery of adenovirus in the 3 main

123 ression of SERCA2a by in vivo rAAV1-mediated intracoronary gene transfer preserved systolic function,

124 ndocardial group (+8.1 +/- 4.3%) than in the intracoronary group (+4.2 +/- 2.3%, P=0.03).

125 ndocardial group (19.2 +/- 4.8%) than in the intracoronary group (4.4 +/- 1.2%, P<0.01).

126 In the intracoronary group, cells were injected intracoronarily

127 endocardial group versus +86 +/- 13 m in the intracoronary group, P=0.03) and N-terminal pro-brain na

128 rdial group versus 103 +/- 27 x 10(6) in the intracoronary group, P=0.62).

129 e index, compared with established hyperemic intracoronary hemodynamic parameters, because achievemen

130 Intracoronary hyperoxemic reperfusion was safe and well

131 r cells (PBMNCs) after intramyocardial (IM), intracoronary (IC), and interstitial retrograde coronary

132 rctions, few high-risk plaques identified by intracoronary imaging actually result in future major ad

133 The highest-resolution intracoronary imaging modality, optical coherence tomogr

134 Intracoronary imaging provides unique insights to unrave

135 and coronary blood flow quantification, and intracoronary imaging to detect early changes in the ves

136 onsible for MACE and improves the ability of intracoronary imaging to predict events.

137 vention is also due to important advances in intracoronary imaging, and adjunct pharmacotherapy-each

138 ilability and application of high-resolution intracoronary imaging.

139 After retrograde intracoronary implantation of beta-galactosidase-express

140 Intracoronary implantation of the EES is associated with

141 of heart failure, overexpression of I-1c by intracoronary in vivo gene transfer preserved cardiac fu

142 ogic analysis was used to confirm successful intracoronary infiltration of MGd and trypan blue within

143 million autologous CSCs were administered by intracoronary infusion at a mean of 113 days (SE 4) afte

144 ed split between the guiding catheter and an intracoronary infusion catheter.

145 injection and intravenous infusion, whereas intracoronary infusion demonstrated no improvement.

146 1.3), as did intravenous infusion, but again intracoronary infusion demonstrating no improvement.

147 IE) was delivered into cardiac allografts by intracoronary infusion ex vivo.

148 ioactivity of autologous CD34+ cell (CLBS10) intracoronary infusion in patients with left ventricular

149 res may be viable therapeutic candidates for intracoronary infusion in selected myocardial disorders.

150 cardial injection, intravenous infusion, and intracoronary infusion indicated no improvement.

151 and web-response system, to receive a single intracoronary infusion of 1 x 10(13) DNase-resistant par

152 d 2-3 weeks later were randomized to receive intracoronary infusion of 12.5x10(6) mismatched allogene

153 Intracoronary infusion of 150 x 10(6) autologous BMCs (t

154 Intracoronary infusion of 150 x 106 BMCs or placebo (ran

155 33 severe) were randomized to receive either intracoronary infusion of 3 incremental doses of eMSC or

156 t failure therapy were randomized to receive intracoronary infusion of AAV1/SERCA2a in 1 of 3 doses (

157 After a single intracoronary infusion of AAV1/SERCA2a in patients with

158 Intracoronary infusion of allogeneic MPCs is safe, feasi

159 dysfunction following reperfusion with PCI, intracoronary infusion of autologous BMCs vs intracorona

160 However, the responses after intracoronary infusion of autologous bone marrow-derived

161 INTERPRETATION: We show intracoronary infusion of autologous CDCs after myocardi

162 Intracoronary infusion of autologous CSCs improves regio

163 They suggest that intracoronary infusion of autologous CSCs is effective i

164 LV dysfunction after successful reperfusion, intracoronary infusion of BM-MNC at either 5 to 7 days o

165 might be recommended as an anticoagulant for intracoronary infusion of BMCs for cell therapy after ca

166 ment were randomized to receive double-blind intracoronary infusion of BMCs or placebo, and patients

167 tients receiving placebo shock wave received intracoronary infusion of BMCs.

168 Intracoronary infusion of BMMNC is safe, but does not en

169 RATIONALE: Intracoronary infusion of bone marrow (BM) mononuclear c

170 ction induced by ischemia/reperfusion before intracoronary infusion of CDCexo, inert fibroblast exoso

171 The intracoronary infusion of cells imposes the potential ri

172 vestigate the efficacy of different doses of intracoronary infusion of eMSC in a porcine model of acu

173 g coronary angioplasty were randomized to an intracoronary infusion of enalaprilat or placebo, follow

174 Intracoronary infusion of fibrin-specific thrombolytic t

175 In an isolated heart model, intracoronary infusion of IL-18BP MSCs before ischemia i

176 sel stenosis were studied at rest and during intracoronary infusion of nitroglycerin (0.3 to 0.6 micr

177 Intracoronary infusion of progenitor cells can be perfor

178 sine-induced maximal hyperemia as reference, intracoronary infusion of saline at rates of 5, 10, 15,

179 Intracoronary infusion of saline at room temperature thr

180 metric coronary blood flow, we observed that intracoronary infusion of saline increased coronary flow

181 h angiographically normal coronary arteries, intracoronary infusion of SMTC (0.625 micromol/min) redu

182 nary occlusion/reperfusion, rats received an intracoronary infusion of vehicle or enhanced green fluo

183 Retrograde intracoronary infusion will offer an effective, direct a

184 796863), the authors assessed the effects of intracoronary infusion with bone marrow-derived mononucl

185 vered by means of direct surgical injection, intracoronary infusion, retrograde venous infusion, and

186 al in the setting of an old MI when given by intracoronary infusion, the most widely applicable thera

187 ells; N=78) or (2) diluent alone (N=83), via intracoronary infusion.

188 , have been associated with infarction after intracoronary infusion.

189 ing was performed after consecutive 5-minute intracoronary infusions (vehicle solution, 0.30 mug/min

190 change in coronary blood flow in response to intracoronary infusions of acetylcholine during diagnost

191 ardiomyopathy, 20 were randomized to receive intracoronary injection and 20 received transendocardial

192 Dynamic tracking during intracoronary injection of (18)F-FDG-labeled CPC is feas

193 We used intracoronary injection of a replication-deficient adeno

194 Intracoronary injection of AAV9.I-1c prevented further d

195 Intracoronary injection of autologous BMNCs does not imp

196 35, and optimized therapy were randomized to intracoronary injection of autologous BMNCs or placebo.

197 ricular tachycardia for the initial 14 days; intracoronary injection of BM cells and intramyocardial

198 Both intramyocardial and intracoronary injection of BM cells demonstrated similar

199 though various approaches have been studied, intracoronary injection of bone marrow autologous mononu

200 We investigated whether intracoronary injection of nitrite during primary percut

201 rdial repair through a clinically applicable intracoronary injection protocol in a pig model of myoca

202 ulating progenitor cell (CPC) therapy during intracoronary injection, using a porcine model of acute

203 udy has shown that liposome-mediated ex vivo intracoronary interleukin (IL)-4 and IL-10 combined gene

204 cell delivery have been reported, including intracoronary, intramyocardial, intravenous, and epicard

205 Intracoronary levosimendan (3.75 and 12.5 microg/min for

206 bing findings suggestive of angiographic and intracoronary manifestations of coronary FMD.

207 Using intracoronary measurements, 91 coronaries (78 patients)

208 n emission tomography and its interplay with intracoronary measurements.

209 In one study, dogs with intracoronary microembolization-induced HF were randomiz

210 rcts were created in Yorkshire pigs (n=6) by intracoronary microsphere injection.

211 c hibernating myocardium received autologous intracoronary MSCs (icMSCs; approximately 44 x10(6) cell

212 uvastatin 40 mg for 8-12 weeks and underwent intracoronary multimodality imaging of an obstructive no

213 tervention for a culprit lesion, followed by intracoronary multimodality imaging, including optical c

214 In this study, intracoronary near-infrared spectroscopy (NIRS) was used

215 determine the long-term prognostic value of intracoronary NIRS as assessed in a nonculprit vessel in

216 vasomotor reactivity after administration of intracoronary nitrate.

217 he stenosis were measured at baseline, after intracoronary nitrates, and after stent PCI.

218 ng that a phase III clinical trial assessing intracoronary nitrite administration as an adjunct to pe

219 In this phase II study, intracoronary nitrite infusion did not alter infarct siz

220 nderwent coronary diameter measurement after intracoronary nitroglycerin injection 5, 20, and 35 mm d

221 pacing for endothelium-dependent cases; and intracoronary nitroglycerin injection for endothelium-in

222 However, administration of cells requires intracoronary or intracardiac instrumentation, which is

223 IDA STEMI trial randomized 2,065 patients to intracoronary or intravenous abciximab and found similar

224 ents with and without diabetes randomized to intracoronary or intravenous abciximab bolus at the time

225 coronary syndrome were randomized to either intracoronary or intravenous bolus administration of ept

226 egment shift during inflations on either the intracoronary or the surface ECG.

227 ing utilized to further our understanding of intracoronary pathology and the effects of therapies bot

228 s performed to calculate aortic (Pa), distal intracoronary (Pd), and reservoir (Pr) pressure at basel

229 stable coronary artery disease who underwent intracoronary physiological evaluation of >/= 1 coronary

230 of functional coronary lesion severity using intracoronary physiological parameters such as coronary

231 intracoronary infusion of autologous BMCs vs intracoronary placebo infusion, 2 to 3 weeks after PCI,

232 ct of short-term intensive statin therapy on intracoronary plaque lipid content.

233 mbus aspirate analysis showed persistence of intracoronary polymer fragments in case 1.

234 Intracoronary polymer-based stent delivery of paclitaxel

235 l to the stenosis; in part 2 (118 stenoses), intracoronary pressure alone was measured.

236 Simultaneous intracoronary pressure and flow velocity recordings were

237 In 51 vessels, intracoronary pressure and flow velocity was measured di

238 Intracoronary pressure and flow velocity were measured a

239 In part 1 (39 stenoses), intracoronary pressure and flow velocity were measured d

240 Intracoronary pressure and flow velocity were measured i

241 Intracoronary pressure and flow velocity were simultaneo

242 Small drifts in intracoronary pressure measurements (+/-2 mm Hg) can aff

243 ed by the thermodilution technique using the intracoronary pressure wire in 38 stenoses in 34 patient

244 Immediately after successful PCI, intracoronary pressure-flow measurements were performed

245 lysis identified a wave-free period in which intracoronary resistance at rest is similar in variabili

246 Intracoronary resistance is naturally constant and minim

247 f animals were not transplanted but received intracoronary rIFN-gamma infusion into the native heart.

248 of autologous CD34(+) cells delivered via an intracoronary route after recent myocardial infarction i

249 oth P-selectin and ICAM-1 via the retrograde intracoronary route could be a promising new strategy fo

250 However, the more desirable intracoronary route has been assumed to be unsafe for ca

251 ardial biopsy specimens were infused via the intracoronary route in 17 patients with left ventricular

252 th P-selection and ICAM-1 via the retrograde intracoronary route to attenuate myocardial ischemia-rep

253 peptide, and exercise capacity compared with intracoronary route.

254 ch arrhythmias may be prevented by using the intracoronary route.

255 her a direct intramyocardial or a retrograde intracoronary route.

256 icle solution, 0.30 mug/min and 0.60 mug/min intracoronary salbutamol) to measure changes in segmenta

257 Intracoronary saline given on top of an intravenous infu

258 Intracoronary saline infusion did not affect blood press

259 thoracic echocardiography during a prolonged intracoronary saline infusion.

260 ngle vessel coronary artery disease and mean intracoronary shear estimates at 2935 seconds(-1) (peak

261 mic minipigs (n=5) were instrumented with an intracoronary shear-modifying stent (SMS).

262 Intracoronary stem cell transplantation may be associate

263 ificant coronary artery disease receiving an intracoronary stent between April 2004 and December 2007

264 onary syndromes, 11 289 (61%) had at least 1 intracoronary stent.

265 The aim of the ISAR-ASPI (Intracoronary Stenting and Antithrombotic Regimen-ASpiri

266 nt Intervention Triage Strategy (ACUITY) and Intracoronary Stenting and Antithrombotic Regimen: Rapid

267 The ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid

268 being challenged by recent clinical trials (Intracoronary Stenting and Antithrombotic Regimen: Rapid

269 : Rapid Early Action for Coronary Treatment, Intracoronary Stenting and Antithrombotic Regimen: Rapid

270 Intracoronary stenting can improve procedural success an

271 atients with atrial fibrillation who undergo intracoronary stenting traditionally are treated with a

272 l methodologies confirmed the finding of the Intracoronary Stenting With Antithrombotic Regimen Cooli

273 only, small, randomized clinical trial, the Intracoronary Stenting With Antithrombotic Regimen Cooli

274 patients with atrial fibrillation undergoing intracoronary stenting, administration of either rivarox

275 udy examining consecutive patients receiving intracoronary stents at Duke Heart Center, a tertiary ca

276 ervention (PCI), which involves placement of intracoronary stents in most patients, is a less invasiv

277 Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet r

278 tensive platelet inhibition in patients with intracoronary stents.

279 idly become a preferred modality for imaging intracoronary structures such as coronary plaques and co

280 had no effect on increases in flow evoked by intracoronary substance P (20 pmol/min).

281 ents who might benefit from further adjuvant intracoronary therapies, such as thrombolysis, vasodilat

282 r development of molecular MR imaging-guided intracoronary therapy.

283 elements in patients who succumbed to fatal intracoronary thrombosis.

284 atient population with a high probability of intracoronary thrombosis.

285 Persistent intracoronary thrombus after plaque rupture is associate

286 The clinical effect of routine intracoronary thrombus aspiration before primary percuta

287 Routine intracoronary thrombus aspiration before primary percuta

288 Ten patients were found to have intracoronary thrombus on x-ray coronary angiography (le

289 tery disease (atherosclerotic plaques and/or intracoronary thrombus).

290 motor tone after CTO reopening suggests that intracoronary ultrasound assessment is of paramount impo

291 el segments, showing a good correlation with intracoronary ultrasound.

292 Intracoronary ultrasounds failed to show changes of the

293 13 patients, distal vessels were assessed by intracoronary ultrasounds.

294 ular tachycardia, which was only resolved by intracoronary vasodilator injection.

295 patients to date demonstrates no benefit of intracoronary versus intravenous abciximab administratio

296 udy was to investigate potential benefits of intracoronary versus intravenous abciximab bolus adminis

297 Among diabetic patients, intracoronary versus intravenous abciximab bolus was ass

298 tor occupancy was significantly greater with intracoronary versus intravenous administration: first b

299 yocardial infarction frame count (cTFC) with intracoronary versus intravenous administration: pre-PCI

300 ultaneous pressure and Doppler velocity with intracoronary wires in the left main stem, left anterior